Anticoagulation is ubiquitous in critical care. Considering the use of DVT prophylaxis, the majority of critically ill patients will receive some form of anticoagulation during their ICU stay. Anticoagulants are potentially high-risk medications, with relatively narrow therapeutic windows. Thus, it's important to understand the pharmacology of various agents to select and monitor anticoagulation optimally.
-
The IBCC chapter is located here.
- The podcast & comments are below.
Follow us on iTunes
The Podcast Episode
Want to Download the Episode?
Right Click Here and Choose Save-As
Josh is the creator of PulmCrit.org. He is an associate professor of Pulmonary and Critical Care Medicine at the University of Vermont.
Latest posts by Josh Farkas (see all)
- IBCC chapter – Disseminated Intravascular Coagulation (DIC) - January 18, 2021
- PulmCrit- RCTs don't justify using convalescent plasma or antibody cocktails - January 14, 2021
- PulmCrit – Six RCTs to answer one question: what is the role of tocilizumab in COVID-19? - January 12, 2021
I’m interested in pre-hospitalization treatment including dabigatran or another DOAC, at least at a low dose. One knock is possible drug interaction with an antiviral, but there doesn’t seem to be much enthusiasm for antivirals anyway. Could a DOAC and an interferon be used together?
Concerning the hospitalized, I wonder if your thinking tracks with this document from Emory: https://www.emoryhealthcare.org/ui/pdfs/covid/medical-professionals/COVID%20Emory%20VTE%20Guidelines%20FINAL.pdf